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Tissue origin No. of cell lines 
Leukemia 6 
Non-Small Cell Lung 9 
Colon 7 
CNS 6 
Melanoma 9 
Ovarian 7 
Renal 8 
Prostate 2 
Breast 6 
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Source Extracts Organisms No. 
hits 
Hit Rate 
(%) 
Mediterranean 
sponge fungi 
754 206 78 10.3 
Chilean macro-
algal fungi 
125 125 48 38.4 
Indonesian 
coral fungi 
331 105 47 16.5 
Totals 1210 436 173 14.3 
Structure of the Marine Fungi consortium 
Summary of the collected fungi, their natural 
products and the corresponding bioactivity 
The ‚Marine Fungi‘ 
project, an inter-
national FP7 
program, aims at 
identification of 
novel compounds 
with anticancer 
properties from 
marine fungi. The 
projects spans        
s from the isolation and characterisation of the marine fungi to fermentation, activity guided purification and 
screening of extracts and compounds. The 3 most interesting natural products are now being analysed in vivo. 
Schematic representation of 
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M14 cells (melanoma) on 
Dextran Microcarriers 
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Direct comparison of 258 compounds 
screened against A549 cells in 2D and 3D 
(R2=0.95) 
Next to conven-
tional plate based 
assays dextran 
microcarriers 
were evaluated. 
56 Hits from the 
screen were 
followed up in 
dose response. No 
significant 
differences were 
observed. 3D data 
confirm 2D 
experiments.  
Brightfield images of A549 
cells after 3, 24, 48 and 72h 
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Brightfield images of A549 
cells after 3, 24, 48 and 72h 
Comparison of cell growth 
using CTG (grey) or image 
based (black) analyses. 
Comparison of cell growth 
using CTG (grey) or image 
based (black) analyses. 
Marine Fungi cytotoxicity assay 
principle based on the NIH procedure. 
By detecting viability at day 1 
cytostatic and cytotoxic compounds 
can be identified 
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Tissue specific composition of the NCI60 
cell line panel. 
Schematic representation of dose-
response curves obtained with the 
characteristic cellular parameters. 
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Structures of myco-
phenolic acid (1), 
penitrem A (2), 
rugulosin (3) 
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Normalised Cell Growth 
dose response curves for 
secalonic acid in 786-0, 
MCF-7, M14 and HL-60 cell 
lines showing TGI values 
between 8 and 30 µM 
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Normalised Cell Growth 
dose response curves for 
bisdethiobis- (methylthio)-
gliotoxin in 786-0, MCF-7, 
M14 and HL-60 cell lines 
Frequency distribution of GI50 (white), 
TGI (grey) and LC50 (black) values 
(µM) for 37 compounds against the 
same 4 cell lines 
Binned LC50 / TGI / GI50 (µM) 
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Mitotox assay based on image analysis. Read out is the 
area of viable Mitochondria. IC50 of Valinomycin varies 
between 13 and 19 nM. 
The principle of the NCI60 human 
tumour cell line anticancer drug 
screen was developed 15 years ago. 
We adapted the assay for HTS 
purposes by changing the read out, 
from dye based to Lumines-cence, 
miniaturising it, from 96 to 384 well 
plates, and reducing the volume 
per well from 200 µl to 20 µl. The 
wealth of data available for the cell 
lines from the NCI60 panel, like 
COMPARE or the COSMIC database, 
is an invaluable source of 
information for the screening 
process. Parallel to the NIH 
procedure assays for improved 
automatisation, using the 
BioLevitator™ (Hamilton Bonaduz 
AG), or alternative read outs, using 
the CellMetric™ (Solentim Ltd), 
were evaluated. 
The screening process is based on a triage of assays. Starting 
with 4 very sensitive cell lines from the NCI60 to identify 
also weak anticancer activity, the compounds then undergo 
a full screening in the NCI60 panel to obtain tissue specific 
data and an understanding of the mode of action via 
COMPARE. Most of the marine natural products exhibit an 
activity in the low micromolar range. 
Further assays include apoptosis and necrosis assays as well 
as pathway analysis using PhosphoFlow analysis. ADMET 
assays like plasma protein binding or Cytochome P450 
inhibition help to select the most interesting compounds for 
in-vivo studies. 
A research article describing the identification of the first 37 
identified natural products has been submitted and will 
appear in the journal for ASSAY and Drug Development 
Technologies. 
